Evidence for the participation of peripheral 5-HT₂A, 5-HT₂B, and 5-HT₂C receptors in formalin-induced secondary mechanical allodynia and hyperalgesia

Neuroscience. 2013 Mar 1:232:169-81. doi: 10.1016/j.neuroscience.2012.11.047. Epub 2012 Dec 3.

Abstract

The role of 5-HT₂A/₂B/₂C receptors in formalin-induced secondary allodynia and hyperalgesia in rats was assessed. Formalin produced acute nociceptive behaviors (flinching and licking/lifting) followed by long-term secondary mechanical allodynia and hyperalgesia. Pre-treatment for five consecutive days with compound 48/80 (1, 3, 10, 10, and 10 μg/paw) prevented formalin-induced secondary allodynia and hyperalgesia. Ipsilateral, but not contralateral, peripheral pre-treatment (nmol/paw) with the 5-HT₂ receptor agonist DOI (3-30), 5-HT (10-100) or fluoxetine (0.3-3) significantly increased 0.5% formalin-induced secondary allodynia and hyperalgesia in both paws. The pronociceptive effect of DOI (10 nmol/paw), 5-HT (100 nmol/paw) and fluoxetine (1 nmol/paw) was blocked by selective 5-HT₂A (ketanserin), 5-HT₂B (RS-127445), and 5-HT₂C (RS-102221) receptor antagonists. Furthermore, ipsilateral pre-treatment (nmol/paw) with ketanserin (1, 10, and 100), RS-127445 (0.01, 0.1 and 1) or RS-102221 (1, 10 and 100) prevented while post-treatment reversed 1% formalin-induced secondary allodynia and hyperalgesia in both paws. In marked contrast, contralateral injection of the greatest tested dose of 5-HT₂A/₂B/₂C receptor antagonists did not modify long-lasting secondary allodynia and hyperalgesia. These results suggest that 5-HT released from mast cells after formalin injection sensitizes primary afferent neurons via 5-HT₂A/₂B/₂C receptors leading to the development and maintenance of secondary allodynia and hyperalgesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamines / pharmacology
  • Analgesics / pharmacology
  • Animals
  • Dose-Response Relationship, Drug
  • Female
  • Fluoxetine / pharmacology
  • Formaldehyde / toxicity*
  • Hyperalgesia / chemically induced*
  • Hyperalgesia / drug therapy
  • Hyperalgesia / metabolism*
  • Ketanserin / pharmacology
  • Pyrimidines / pharmacology
  • Rats, Wistar
  • Receptor, Serotonin, 5-HT2A / metabolism*
  • Receptor, Serotonin, 5-HT2B / metabolism*
  • Receptor, Serotonin, 5-HT2C / metabolism*
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin / administration & dosage
  • Serotonin Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology
  • Spiro Compounds / pharmacology
  • Sulfonamides / pharmacology
  • p-Methoxy-N-methylphenethylamine / pharmacology

Substances

  • 8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione
  • Amphetamines
  • Analgesics
  • Pyrimidines
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2B
  • Receptor, Serotonin, 5-HT2C
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Spiro Compounds
  • Sulfonamides
  • Fluoxetine
  • 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine
  • Formaldehyde
  • Serotonin
  • p-Methoxy-N-methylphenethylamine
  • Ketanserin
  • 4-iodo-2,5-dimethoxyphenylisopropylamine